Gina McKnight-Smith, Pharm D, MBA, CGP, BCPS, CHTS-CP

Capitol Urology, PA

1333 Taylor St

Suite 2-B




Drugs in Perspective: Opdivo (nivolumab)

March 23, 2015

On December 22, 2014, Opdivo (nivolumab) was approved by FDA with a breakthrough therapy designation. Nivolumab is the second human programmed death-1 (PD-1) receptor-blocking antibody to gain accelerated approval for treatment of patients with unresectable or metastatic melanoma and disease progression following Yervoy (ipilimumab) and, if BRAF V600 mutation positive, a BRAF inhibitor.